对急性脑梗死患者中高同型半胱氨酸的临床评价  

Clinical evaluation of high homocysteine in acute cerebral infarction

作　　者：李凤娥 成振华[1] 刘文运[1] 郭荣云[1] 郭锋[1] Li Fenge;Cheng Zhenhua;Liu Wenyun;Guo Rongyun;Guo Feng(Department of Neurology,the People's Hospital of Lvliang City,Shanxi Province 033000)

机构地区：[1]山西省吕梁市人民医院神经内科,033000

出　　处：《中国社区医师》2018年第26期132-133,共2页Chinese Community Doctors

摘　　要：目的:探讨高同型半胱氨酸在急性脑梗死患者中临床评价。方法:收治急性脑梗死患者96例,分成对照组和观察组。检测血浆同型半胱氨酸相关水平,分析两组患者在治疗期间日常生活的能力和对神经功能的损伤状况。结果:两组患者在空腹时其血浆同型半胱氨酸的水平比较,差异有统计学意义(P<0.05)。两组在发病第1天、7天、14天对各指标予以评分,差异无统计学意义(P>0.05)。结论:对急性脑梗死患者,在发病<2周其高同型半胱氨酸临床疗效评价,短时期的预后效果没有相关性。Objective:To explore the clinical effect of high homocysteine in acute cerebral infarction.Methods:96 patients with acute cerebral infarction were selected,they were divided into control group and observation group,we analyzed the daily living ability and nerve function damage of the two groups during the treatment.Results:There was no significant difference of each indexes between the two groups in the first day,7 days,and 14 days of onset(P>0.05).Conclusion:For the patients with acute cerebral infarction,there was no correlation between the high homocysteine within 2 weeks after the onset and evaluation of clinical efficacy and effect of short period prognosis.

关 键 词：急性脑梗死 高同型半胱氨酸 临床评价 

分 类 号：R743.33[医药卫生—神经病学与精神病学]